PA8540101A1 - Metodo para el tratamiento de enfermedades o condiciones por desmielinizacion - Google Patents

Metodo para el tratamiento de enfermedades o condiciones por desmielinizacion

Info

Publication number
PA8540101A1
PA8540101A1 PA20028540101A PA8540101A PA8540101A1 PA 8540101 A1 PA8540101 A1 PA 8540101A1 PA 20028540101 A PA20028540101 A PA 20028540101A PA 8540101 A PA8540101 A PA 8540101A PA 8540101 A1 PA8540101 A1 PA 8540101A1
Authority
PA
Panama
Prior art keywords
treatment
disease
conditions
useful
components
Prior art date
Application number
PA20028540101A
Other languages
English (en)
Inventor
Craig P Smith
David Rampe
Margaret Petty
Michel P Rathbone
Original Assignee
Aventis Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Inc filed Critical Aventis Pharma Inc
Publication of PA8540101A1 publication Critical patent/PA8540101A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

EL N-(PIRIDINIL)-1H-INDOL-1-AMINA DE LA FORMULA I PROPORCIONA UNA COMBINACION UNICA DE PROPIEDADES BLOQUEADORES PARA AMBOS CANALES DE POTASIO Y DE SODIO. ESTOS COMPONENTES SON UTILES PARA EL TRATAMIENTO DE LAS ENFERMEDADES Y CONDICIONES POR DESMIELINIZACION COMO LA ESCLEROSIS MULTIPLE, LESIONES EN LA MEDULA ESPINAL, LESIONES CEREBRALES TRAUMATICAS Y GOLPES. ESTOS COMPONENTES SON UTILES TAMBIEN PARA LA REHABILITACION POR GOLPES, EL TRATAMIENTO DE INFLAMACION DE LA VEJIGA Y DISFUNCIONES, EL TRATAMIENTO DE DOLORES NEUROPATICOS Y DOLORES INDUCIDOS.
PA20028540101A 2001-02-15 2002-02-18 Metodo para el tratamiento de enfermedades o condiciones por desmielinizacion PA8540101A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US26884601P 2001-02-15 2001-02-15

Publications (1)

Publication Number Publication Date
PA8540101A1 true PA8540101A1 (es) 2003-09-05

Family

ID=23024747

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20028540101A PA8540101A1 (es) 2001-02-15 2002-02-18 Metodo para el tratamiento de enfermedades o condiciones por desmielinizacion

Country Status (39)

Country Link
US (10) US6967210B2 (es)
EP (1) EP1368031A2 (es)
JP (3) JP2004518711A (es)
KR (3) KR100951540B1 (es)
CN (2) CN100522164C (es)
AP (1) AP1749A (es)
AR (1) AR035750A1 (es)
AU (3) AU2002247200B9 (es)
BR (1) BR0207272A (es)
CA (1) CA2438712A1 (es)
CO (1) CO5390085A1 (es)
CR (1) CR7023A (es)
CZ (1) CZ20032172A3 (es)
EA (2) EA012409B1 (es)
EC (1) ECSP024218A (es)
EE (1) EE200300363A (es)
GB (1) GB0119435D0 (es)
HK (1) HK1080361B (es)
HR (1) HRP20030652A2 (es)
HU (1) HUP0303203A3 (es)
IL (2) IL157341A0 (es)
MA (1) MA26152A1 (es)
ME (1) MEP21208A (es)
MX (1) MXPA03006110A (es)
MY (1) MY157745A (es)
NO (1) NO20033622L (es)
NZ (4) NZ544720A (es)
OA (1) OA12549A (es)
PA (1) PA8540101A1 (es)
PE (1) PE20040175A1 (es)
PL (1) PL363638A1 (es)
SG (1) SG134170A1 (es)
SK (1) SK10392003A3 (es)
TR (4) TR200301330T2 (es)
TW (1) TWI325319B (es)
UA (2) UA80394C2 (es)
WO (1) WO2002064126A2 (es)
YU (1) YU62903A (es)
ZA (1) ZA200306124B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0119435D0 (en) * 2001-02-15 2001-10-03 Aventis Pharm Prod Inc Method of treating of demyelinating diseases or conditions
BR0317606A (pt) * 2002-12-20 2005-11-29 Dynogen Pharmaceuticals Inc Métodos de tratamento de distúrbios não dolorosos da bexiga urinária que usam moduladores de canal de cálcio de subunidade (alfa)2(delta)
AU2004207010A1 (en) * 2003-01-30 2004-08-12 Dynogen Pharmaceuticals, Inc. Methods of treating lower urinary tract disorders using sodium channel modulators
US20040198822A1 (en) * 2003-03-21 2004-10-07 Dynogen Pharmacueticals, Inc. Methods for treating lower urinary tract disorders using alpha2delta subunit calcium channel modulators with smooth muscle modulators
GT200500063A (es) * 2004-04-01 2005-10-14 Metodo para tratar la esquizofrenia y/o anormalidades glucoregulatorias
GB0510164D0 (en) * 2005-04-28 2005-06-22 Paradigm Therapeutics Ltd Ion channel
FR2892022B1 (fr) * 2005-10-19 2008-01-04 Urogene Sa Traitement des symptomes de l'irritation de la vessie
FR2892021B1 (fr) * 2005-10-19 2008-01-04 Urogene Traitement de l'incontinence urinaire d'effort et mixte
US8420593B1 (en) * 2006-06-16 2013-04-16 Landon C. G. Miller Compositions and methods for regulating membrane potential
DE102008044844B4 (de) * 2008-08-28 2018-08-30 Siemens Healthcare Gmbh Verfahren zur Ermittlung einer Schwächungskarte zur Verwendung in der Positronenemissionstomographie und von Homogenitätsinformationen des Magnetresonanzmagnetfeldes
KR101862539B1 (ko) * 2010-03-26 2018-05-31 가부시키가이샤 한도오따이 에네루기 켄큐쇼 반도체 장치
US20130184316A1 (en) * 2010-07-15 2013-07-18 Andrew Hornstein Methods for diagnosing and treating concussive disorders
EP2995305B1 (en) * 2011-01-28 2020-03-04 Acorda Therapeutics, Inc. Use of potassium channel blockers to treat cerebral palsy
TWI592156B (zh) * 2011-10-04 2017-07-21 艾可達醫療公司 使用胺基吡啶以治療與中風有關之感覺動作損傷之方法
US20190060286A1 (en) 2016-02-29 2019-02-28 University Of Florida Research Foundation, Incorpo Chemotherapeutic Methods
EP3727587A4 (en) 2017-12-22 2022-02-23 Massachusetts Institute Of Technology COMPOSITIONS AND METHODS FOR THERAPY OF WILLIAMS SYNDROME (WS)
CN116723870A (zh) * 2021-01-20 2023-09-08 拉什大学医学中心 球形细胞脑白质营养不良症或克拉伯病的改良治疗

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4880822A (en) * 1987-04-24 1989-11-14 Hoechst-Roussel Pharmaceuticals, Inc. N-(pyridinyl)-1H-indol-1-amines
US4970218A (en) * 1987-04-24 1990-11-13 Hoechst-Roussel Pharmaceuticals Inc. N-(pyridinyl)-1H-indol-1-amines
ATE115143T1 (de) * 1987-04-24 1994-12-15 Hoechst Roussel Pharma N-(pyridinyl)-1h-indol-1-amine, verfahren zu deren herstellung und ihre verwendung als arzneimittel.
IL95251A (en) * 1989-08-02 1996-08-04 Hoechst Roussel Pharma 2,3-Dihydro-1- (pyridinylamino) - indoles, a method for their preparation and use as drugs
US5214038A (en) * 1991-04-15 1993-05-25 Hoechst-Roussel Pharmaceuticals Inc. 1-(pyrido[3,4-b]-1,4-oxazinyl-4-yl)-1H-indoles and intermediates for the preparation thereof
DE4325491A1 (de) * 1993-07-29 1995-02-02 Boehringer Ingelheim Kg Verwendung von zentral wirksamen alpha-2-Agonisten zur Hemmung des Postaggressionsstoffwechsels
US5459274A (en) * 1994-05-13 1995-10-17 Hoechst-Roussel Pharmaceuticals Inc. Preparation of N-alkyl-N-pyridinyl-1H-indol-1-amines
US5565475A (en) * 1994-11-08 1996-10-15 Muhlhauser; Mark A. Method of treating urinary bladder dysfunctions with 3-tetrahydropyridine derivatives
EP0731108A1 (en) * 1995-03-10 1996-09-11 Boehringer Mannheim Gmbh Method of manufacturing a therapeutic agent for the regeneration of oligodendrocytes
FR2754147B1 (fr) 1996-10-03 2000-02-04 Mbh Technologies Sa Installation et procede pour le traitement de carcasses
DK1056754T3 (da) * 1998-01-29 2004-02-16 Bristol Myers Squibb Co Phosphatderivater af diaryl-1,3,4-oxadiazolon
WO2001004091A1 (en) * 1999-07-09 2001-01-18 Ortho-Mcneil Pharmaceutical, Inc. Neurotrophic 2-azetidinecarboxylic acid derivatives, and related compositions and methods
GB0119435D0 (en) * 2001-02-15 2001-10-03 Aventis Pharm Prod Inc Method of treating of demyelinating diseases or conditions

Also Published As

Publication number Publication date
HRP20030652A2 (en) 2005-06-30
JP2010120958A (ja) 2010-06-03
US20050234105A1 (en) 2005-10-20
NZ544720A (en) 2007-08-31
SG134170A1 (en) 2007-08-29
CO5390085A1 (es) 2004-04-30
HUP0303203A3 (en) 2007-11-28
US7230015B2 (en) 2007-06-12
EA012409B1 (ru) 2009-10-30
US20050159456A1 (en) 2005-07-21
WO2002064126A3 (en) 2003-02-20
US7534803B2 (en) 2009-05-19
US6967210B2 (en) 2005-11-22
JP2009185045A (ja) 2009-08-20
CR7023A (es) 2003-11-17
US20090209594A1 (en) 2009-08-20
AU2002247200B2 (en) 2007-12-13
PL363638A1 (en) 2004-11-29
TR200800693T2 (tr) 2008-07-21
IL157341A (en) 2010-11-30
AU2008201179A1 (en) 2008-04-03
OA12549A (en) 2006-06-05
US20090270458A1 (en) 2009-10-29
AP2003002834A0 (en) 2003-09-30
US20030105150A1 (en) 2003-06-05
CN100522164C (zh) 2009-08-05
UA80394C2 (en) 2007-09-25
NO20033622D0 (no) 2003-08-14
AU2009238332A1 (en) 2009-12-10
ZA200306124B (en) 2004-11-08
HUP0303203A2 (hu) 2003-12-29
MXPA03006110A (es) 2005-07-01
BR0207272A (pt) 2004-02-10
CZ20032172A3 (cs) 2004-01-14
PE20040175A1 (es) 2004-03-29
SK10392003A3 (sk) 2004-01-08
TWI325319B (en) 2010-06-01
CN1529598A (zh) 2004-09-15
EP1368031A2 (en) 2003-12-10
IL157341A0 (en) 2004-02-19
HK1080361A1 (en) 2006-04-28
KR20090005255A (ko) 2009-01-12
HK1080361B (zh) 2009-10-30
NO20033622L (no) 2003-10-06
US20090209595A1 (en) 2009-08-20
US20090281147A1 (en) 2009-11-12
US20040157888A1 (en) 2004-08-12
AU2002247200B9 (en) 2008-07-10
ECSP024218A (es) 2003-09-24
US20040157889A1 (en) 2004-08-12
EA200300882A1 (ru) 2003-12-25
CN1679564A (zh) 2005-10-12
KR20090005254A (ko) 2009-01-12
TR200800691T2 (tr) 2008-03-21
KR100951540B1 (ko) 2010-04-09
NZ556697A (en) 2009-01-31
TR200301330T2 (tr) 2004-12-21
MA26152A1 (fr) 2004-07-01
KR100951542B1 (ko) 2010-04-09
AU2008201179B2 (en) 2009-08-20
MY157745A (en) 2016-07-15
TR200800692T2 (tr) 2008-03-21
WO2002064126A2 (en) 2002-08-22
EA011319B1 (ru) 2009-02-27
EE200300363A (et) 2003-10-15
US20060025452A1 (en) 2006-02-02
JP2004518711A (ja) 2004-06-24
GB0119435D0 (en) 2001-10-03
AR035750A1 (es) 2004-07-07
UA88773C2 (ru) 2009-11-25
EA200600896A1 (ru) 2006-08-25
US7179821B2 (en) 2007-02-20
MEP21208A (en) 2010-06-10
NZ527011A (en) 2005-07-29
NZ539159A (en) 2006-11-30
KR20040014459A (ko) 2004-02-14
YU62903A (sh) 2006-05-25
CA2438712A1 (en) 2002-08-22
AP1749A (en) 2007-06-13

Similar Documents

Publication Publication Date Title
PA8540101A1 (es) Metodo para el tratamiento de enfermedades o condiciones por desmielinizacion
CY1108808T1 (el) Ενωσεις μοτιλιδης
CY1107054T1 (el) Ενωσεις διτοσυλικου αλατος κιναζολινης
PT1506781E (pt) Composicao para tratamento vaginal
EA200700202A1 (ru) Гетероарильные соединения в качестве бетамиметиков для лечения заболеваний дыхательных путей
BRPI0411743A (pt) método e composições para tratar doenças relacionadas a amilóides
BR0315644A (pt) Piperazinil e diazapanil benzamidas e benzotioamidas
BRPI0415179A (pt) derivados de amida como ligandos de canal de ìon e composições farmacêuticas e métodos de empregar as mesmas
BR0316723A (pt) Derivados de anilinopirazol úteis para o tratamento de diabetes
CR7195A (es) Nuevos derivados de oxazolidinonas como antibacterianos
BRPI0417858A (pt) composto, composição farmacêutica, e, uso de uma composição farmacêutica
BR0211739A (pt) Novas formas polimórficas cristalinas de cloridrato de lercanidipina e processo para preparação das mesmas
EA200200137A1 (ru) Лечение невротических нарушений
CY1107158T1 (el) Νεα παραγωγα της ισοκινολινης, η μεθοδος παρασκευης τους και η χρηση τους για τη θεραπεια των διαταραχων του μελατονινεργικου συστηματος
BR0207693B1 (pt) processo e aparelho para produzir continuamente uma composição elastomérica.
CY1109666T1 (el) Μεθοδος θεραπειας διαταραχων ξηροφθαλμιας και ραγοειδιτιδας
DE60129829D1 (de) Zyklisierte benzamid-neurokinin-antagonisten zur verwendung in therapie
CY1105345T1 (el) Φαινυλαλκινια
ECSP044971A (es) Isoxazolopiridinonas y su uso en el tratamiento de enfermedad de parkinson
ATE334989T1 (de) Antidepressive azaheterocyclylmethyl-derivate von 2,3-dihydro-1,4-dioxino 2,3-föchinoxalin
BR0309996A (pt) Composto, composição farmacêutica, método de tratar ou melhorar doenças ou condições proliferativas, uso de um composto, e, método de tratar ou melhorar doenças inflamatórias
DK1399438T3 (da) Hidtil ukendte heteroarylderivater samt fremstilling og anvendelse heraf
BRPI0408077A (pt) composições e métodos para prevenção e tratamento de doenças relacionadas com endotoxina e condições
EA200401523A1 (ru) Способы применения и композиции для диагностики и лечения инфекционного заболевания
FR2828643B1 (fr) Plaque d'osteosynthese notamment rachidienne